Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Not yet recruiting	Not stated	2026-06-25		NCT07669194

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Hospital of Jiaxing University	36
Second Affiliated Hospital, Zhejiang University, School of Medicine	561
Shaoxing Central Hospital	8
Shaoxing People's Hospital	24
The First Affiliated Hospital of Zhejiang Chinese Medical University	30
Zhejiang Provincial People's Hospital	74
Zhejiang Provincial Tongde Hospital	20
Zhuji People's Hospital of Zhejiang Province	4

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Second Affiliated Hospital, School of Medicine, Zhejiang University	Hangzhou	China	18